BACKGROUND: Rat lung allograft rejection is mediated by collagen type V (col(V)) specific T-helper-cell 17 (Th17) cells. Adoptive transfer of these cells is sufficient to induce rejection pathology in isografts, whereas tolerance to col(V) suppresses allograft rejection. Therefore, we tested whether regulatory T cells from tolerant rats could suppress the Th17-mediated rejection in the syngeneic model of lung transplantation. METHODS: Rats were subjected to syngeneic left lung transplantation, and acute rejection was induced by adoptive transfer of lymph node cells from col(V)-immunized rats. Tolerance was induced by intravenous injection of col(V), and spleen lymphocytes were used for adoptive transfer. CD4+ T cells were depleted using magnetic beads. Lung isografts were analyzed using micro-positron emission tomography imaging and histochemistry. The transvivo delayed type hypersensitivity assay was used to analyze the Th17 response. RESULTS: Adoptive cotransfer of col(V)-specific effector cells with cells from col(V)-tolerized rats suppressed severe vasculitis and bronchiolitis with parenchymal inflammation, and the expression of interleukin (IL)-17 transcripts in mediastinal lymph nodes induced by effector cells alone. Analysis by transvivo delayed type hypersensitivity showed that the reactivity to col(V) was dependent on the presence of tumor necrosis factor-alpha and IL-17 but not interferon-gamma. Depletion of CD4+ T cells from the suppressor cell population abrogated the col(V)-specific protection. CONCLUSION: Th17-mediated acute rejection after lung transplantation is ameliorated by CD4+ col(V)-specific regulatory T cells. The mechanism for this Th17 suppression is consistent with tolerance induction to col(V). The goal of transplantation treatment, therefore, should target Th17 development and not suppression of T-cell activation by suppressing IL-2.
BACKGROUND:Rat lung allograft rejection is mediated by collagen type V (col(V)) specific T-helper-cell 17 (Th17) cells. Adoptive transfer of these cells is sufficient to induce rejection pathology in isografts, whereas tolerance to col(V) suppresses allograft rejection. Therefore, we tested whether regulatory T cells from tolerant rats could suppress the Th17-mediated rejection in the syngeneic model of lung transplantation. METHODS:Rats were subjected to syngeneic left lung transplantation, and acute rejection was induced by adoptive transfer of lymph node cells from col(V)-immunized rats. Tolerance was induced by intravenous injection of col(V), and spleen lymphocytes were used for adoptive transfer. CD4+ T cells were depleted using magnetic beads. Lung isografts were analyzed using micro-positron emission tomography imaging and histochemistry. The transvivo delayed type hypersensitivity assay was used to analyze the Th17 response. RESULTS: Adoptive cotransfer of col(V)-specific effector cells with cells from col(V)-tolerized rats suppressed severe vasculitis and bronchiolitis with parenchymal inflammation, and the expression of interleukin (IL)-17 transcripts in mediastinal lymph nodes induced by effector cells alone. Analysis by transvivo delayed type hypersensitivity showed that the reactivity to col(V) was dependent on the presence of tumor necrosis factor-alpha and IL-17 but not interferon-gamma. Depletion of CD4+ T cells from the suppressor cell population abrogated the col(V)-specific protection. CONCLUSION:Th17-mediated acute rejection after lung transplantation is ameliorated by CD4+ col(V)-specific regulatory T cells. The mechanism for this Th17 suppression is consistent with tolerance induction to col(V). The goal of transplantation treatment, therefore, should target Th17 development and not suppression of T-cell activation by suppressing IL-2.
Authors: T Mizuta; K Nakahara; R Shirakura; Y Fujii; A Kawaguchi; M Minami; Y Kawashima Journal: J Thorac Cardiovasc Surg Date: 1991-07 Impact factor: 5.209
Authors: Michelle N Kelly; Jay K Kolls; Kyle Happel; Joseph D Schwartzman; Paul Schwarzenberger; Crescent Combe; Magali Moretto; Imtiaz A Khan Journal: Infect Immun Date: 2005-01 Impact factor: 3.441
Authors: Alice O Kamphorst; Maria F S da Silva; Antônio C da Silva; Claudia R Carvalho; Ana Maria C Faria Journal: Ann N Y Acad Sci Date: 2004-12 Impact factor: 5.691
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: L A Green; S S Gambhir; A Srinivasan; P K Banerjee; C K Hoh; S R Cherry; S Sharfstein; J R Barrio; H R Herschman; M E Phelps Journal: J Nucl Med Date: 1998-04 Impact factor: 10.057
Authors: Claire L Langrish; Yi Chen; Wendy M Blumenschein; Jeanine Mattson; Beth Basham; Jonathan D Sedgwick; Terrill McClanahan; Robert A Kastelein; Daniel J Cua Journal: J Exp Med Date: 2005-01-17 Impact factor: 14.307
Authors: Jeremy M Lott; Sarita Sehra; Purvi Mehrotra; Elizabeth A Mickler; Amanda J Fisher; Wenwu Zhang; Robert G Presson; Michael F Busk; Shreevrat Goenka; Susan J Gunst; Mark H Kaplan; David S Wilkes; Sally E Wenzel Journal: Am J Respir Crit Care Med Date: 2013-02-15 Impact factor: 21.405
Authors: V Tiriveedhi; N Angaswamy; D Brand; J Weber; A G Gelman; R Hachem; E P Trulock; B Meyers; G Patterson; T Mohanakumar Journal: Clin Exp Immunol Date: 2012-01 Impact factor: 4.330
Authors: Hidemi Suzuki; Mark E Lasbury; Lin Fan; Ragini Vittal; Elizabeth A Mickler; Heather L Benson; Rebecca Shilling; Qiang Wu; Daniel J Weber; Sarah R Wagner; Melissa Lasaro; Denise Devore; Yi Wang; George E Sandusky; Kelsey Lipking; Pankita Pandya; John Reynolds; Robert Love; Thomas Wozniak; Hongmei Gu; Krista M Brown; David S Wilkes Journal: J Immunol Date: 2013-09-16 Impact factor: 5.422